S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Silence Therapeutics Share Forecast, Price & News

GBX 25.49
+0.49 (+1.96%)
(As of 12/2/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
24,286 shs
Average Volume
80,100 shs
Market Capitalization
£22.89 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SLN News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Silence Therapeutics logo

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
£11.35 million
Cash Flow
GBX 4.02 per share
Book Value
GBX 18.20 per share


Pretax Margin




Free Float
Market Cap
£22.89 million
Not Optionable

Company Calendar

Last Earnings


Overall MarketRank

1.51 out of 5 stars

Analyst Opinion: 3.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Silence Therapeutics (LON:SLN) Frequently Asked Questions

Is Silence Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Silence Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLN, but not buy additional shares or sell existing shares.
View analyst ratings for Silence Therapeutics
or view top-rated stocks.

How has Silence Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Silence Therapeutics' stock was trading at GBX 470 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SLN stock has decreased by 94.6% and is now trading at GBX 25.49.
View which stocks have been most impacted by COVID-19

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (LON:SLN) issued its earnings results on Monday, September, 14th. The company reported ($13.70) earnings per share for the quarter, topping the Zacks' consensus estimate of ($21.70) by $8.00.
View Silence Therapeutics' earnings history

What price target have analysts set for SLN?

2 analysts have issued twelve-month price targets for Silence Therapeutics' stock. Their forecasts range from GBX 605 to GBX 605. On average, they expect Silence Therapeutics' stock price to reach GBX 605 in the next twelve months. This suggests a possible upside of 2,273.5% from the stock's current price.
View analysts' price targets for Silence Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Silence Therapeutics' key executives?

Silence Therapeutics' management team includes the following people:
  • Mr. Mark Andrew Rothera, Pres, CEO & Exec. Director (Age 58, Pay $521.23k)
  • Dr. Giles V. Campion M.D., Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director (Age 67, Pay $436.2k)
  • Mr. Craig A. Tooman M.B.A., MBA, Chief Financial Officer (Age 55)
  • Ms. Gem Gokmen Hopkins, Head of IR & Corp. Communications
  • Dr. Barbara A. Ruskin, Sr. VP, Gen. Counsel & Chief Patent Officer (Age 61)
  • Ms. Linnea Elrington, VP & Head of HR
  • Dr. John Strafford, VP & Head of Bus. Devel.
  • Mr. Jørgen Wittendorff, Sr. VP & Head of Manufacturing
  • Dr. Marie Wikstrom Lindholm Ph.D., Sr. VP & Head of Molecular Design

What other stocks do shareholders of Silence Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY), Anchiano Therapeutics (ANCN), Aileron Therapeutics (ALRN), Alkermes (ALKS) and Alfa Financial Software (ALFA).

What is Silence Therapeutics' stock symbol?

Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."

How do I buy shares of Silence Therapeutics?

Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Silence Therapeutics' stock price today?

One share of SLN stock can currently be purchased for approximately GBX 25.49.

How much money does Silence Therapeutics make?

Silence Therapeutics has a market capitalization of £22.89 million and generates £11.35 million in revenue each year.

How many employees does Silence Therapeutics have?

Silence Therapeutics employs 74 workers across the globe.

What is Silence Therapeutics' official website?

The official website for Silence Therapeutics is www.silence-therapeutics.com.

Where are Silence Therapeutics' headquarters?

Silence Therapeutics is headquartered at 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom.

How can I contact Silence Therapeutics?

Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.